Similar articles for PMID: 19074663

Year	Number of Results
1999	3
2000	8
2001	2
2002	7
2003	4
2004	3
2005	8
2006	6
2007	3
2008	9
2009	6
2010	6
2011	4
2012	7
2013	4
2014	3
2015	8
2016	3
2017	3
2018	3
2019	1
2022	1
2024	0

1

Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions.

Palmisano L, Giuliano M, Bucciardini R, Andreotti M, Fragola V, Pirillo MF, Weimer LE, Mancini MG, Vella S. Palmisano L, et al. J Med Microbiol. 2009 Jan;58(Pt 1):121-124. doi: 10.1099/jmm.0.004630-0. J Med Microbiol. 2009. PMID: 19074663 Clinical Trial.

2

Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.

Zheng L, Bosch RJ, Chan ES, Read S, Kearney M, Margolis DM, Mellors JW, Eron JJ, Gandhi RT; DS Clinical Trials Group (ACTG) A5244 Team. Zheng L, et al. Antivir Ther. 2013;18(1):39-43. doi: 10.3851/IMP2323. Epub 2012 Aug 22. Antivir Ther. 2013. PMID: 22914318 Free PMC article. Clinical Trial.

3

Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy.

Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S. Palmisano L, et al. AIDS. 2005 Nov 4;19(16):1843-7. doi: 10.1097/01.aids.0000188426.87538.ed. AIDS. 2005. PMID: 16227792

4

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H. Ostrowski SR, et al. Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x. Scand J Immunol. 2008. PMID: 19055701 Free article.

5

Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.

Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Bonora S, et al. J Med Virol. 2009 Mar;81(3):400-5. doi: 10.1002/jmv.21405. J Med Virol. 2009. PMID: 19152404

6

Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL.

Gianotti N, Galli L, Racca S, Salpietro S, Cossarini F, Spagnuolo V, Barda B, Canducci F, Clementi M, Lazzarin A, Castagna A. Gianotti N, et al. J Antimicrob Chemother. 2012 Jan;67(1):213-7. doi: 10.1093/jac/dkr422. Epub 2011 Oct 10. J Antimicrob Chemother. 2012. PMID: 21987242

7

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients.

Gianotti N, Canducci F, Galli L, Cossarini F, Salpietro S, Poli A, Nozza S, Spagnuolo V, Clementi M, Sampaolo M, Ceresola ER, Racca S, Lazzarin A, Castagna A. Gianotti N, et al. Clin Microbiol Infect. 2015 Jan;21(1):103.e7-103.e10. doi: 10.1016/j.cmi.2014.08.004. Epub 2014 Oct 13. Clin Microbiol Infect. 2015. PMID: 25636935 Free article.

8

Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.

Havlir DV, Koelsch KK, Strain MC, Margot N, Lu B, Ignacio CC, Miller MD, Wong JK; Gilead 903 Study Team. Havlir DV, et al. J Infect Dis. 2005 Apr 1;191(7):1164-8. doi: 10.1086/428588. Epub 2005 Feb 28. J Infect Dis. 2005. PMID: 15747253

9

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D. Hermankova M, et al. JAMA. 2001 Jul 11;286(2):196-207. doi: 10.1001/jama.286.2.196. JAMA. 2001. PMID: 11448283

10

Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study.

Palmisano L, Giuliano M, Bucciardini R, Fragola V, Andreotti M, Galluzzo C, Pirillo MF, Weimer LE, Arcieri R, Germinario EA, Amici R, Mancini MG, Monforte Ad, Castelli F, Caramello P, Vella S; Italian ISS-PART Clinical Centers. Palmisano L, et al. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):39-47. J Acquir Immune Defic Syndr. 2007. PMID: 17972364 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year